Evidence map›Paper›PMID 33520605›Full record

ArticleCurrent pharmacology reports2018

Data-Driven Methods for Advancing Precision Oncology.

Prema Nedungadi, Akshay Iyer, Georg Gutjahr, Jasmine Bhaskar, Asha B Pillai

Open access · greenAbstract read
In one paragraph

Article in Current pharmacology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Prema NedungadiCenter for Research in Analytics & Technology in Education, Amrita Vishwa Vidyapeetham, Amritapuri, Kollam, India.
Akshay IyerCenter for Research in Analytics & Technology in Education, Amrita Vishwa Vidyapeetham, Amritapuri, Kollam, India.
Georg GutjahrCenter for Research in Analytics & Technology in Education, Amrita Vishwa Vidyapeetham, Amritapuri, Kollam, India.
Jasmine BhaskarCenter for Research in Analytics & Technology in Education, Amrita Vishwa Vidyapeetham, Amritapuri, Kollam, India.
Asha B PillaiDivision of Pediatric Hematology/Oncology, Departments of Pediatrics and Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA.
Amrita Vishwa Vidyapeetham · INUniversity of Miami · US

Funding

NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIESR01HL133462 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI PILLAI, ASHA BHASKARAN · 2018 to 2021
$1.7M
NHLBI NIH HHS R01 HL133462
6 · The paper itself

Abstract

purpose of reviewThis article discusses the advances, methods, challenges, and future directions of data-driven methods in advancing precision oncology for biomedical research, drug discovery, clinical research, and practice. RECENT

findingsPrecision oncology provides individually tailored cancer treatment by considering an individual's genetic makeup, clinical, environmental, social, and lifestyle information. Challenges include voluminous, heterogeneous, and disparate data generated by different technologies with multiple modalities such as Omics, electronic health records, clinical registries and repositories, medical imaging, demographics, wearables, and sensors. Statistical and machine learning methods have been continuously adapting to the ever-increasing size and complexity of data. Precision Oncology supportive analytics have improved turnaround time in biomarker discovery and time-to-application of new and repurposed drugs. Precision oncology additionally seeks to identify target patient populations based on genomic alterations that are sensitive or resistant to conventional or experimental treatments. Predictive models have been developed for cancer progression and survivorship, drug sensitivity and resistance, and identification of the most suitable combination treatments for individual patient scenarios. In the future, clinical decision support systems need to be revamped to better incorporate knowledge from precision oncology, thus enabling clinical practitioners to provide precision cancer care. SUMMARY: Open Omics datasets, machine learning algorithms, and predictive models have enabled the advancement of precision oncology. Clinical decision support systems with integrated electronic health record and Omics data are needed to provide data-driven recommendations to assist clinicians in disease prevention, early identification, and individualized treatment. Additionally, as cancer is a constantly evolving disorder, clinical decision systems will need to be continually updated based on more recent knowledge and datasets.

Indexed as

Artificial intelligenceBig data in healthClinical decision supportHealth analyticsOmicsPersonalized medicinePrecision medicinePrecision oncologyPredictive analytics

Identifiers

PMID33520605
PMCPMC7845924
OpenAlexW2793423654

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.